Background: Assessment of individual VTE risk in cancer patients prior to chemotherapy is important. Risk assessment models (RAM) are available but have not been validated for hematological malignancy. We aimed to assess validity of the Vienna Cancer and Thrombosis Study (CATS) score in prediction of VTE in a variety of hematological malignancies. Methods: This is a prospective cohort study conducted on 81 newly diagnosed cancer patients undergoing chemotherapy. Demographic, clinical and cancer related data were collected and patients were followed up for 6 months for VTE events. Khorana score (KS) was calculated. Plasma D-dimer and sP-selectin were measured then V-CATS score was calculated. We assessed modified V-CATS by using new cut off levels of d-dimer and sP-selectin based on ROC curve of the patients’ results. Results: Out of the 81 patients assessed, 2.7% had advanced cancer with metastasis. The most frequent cancer was Non-Hodgkin lymphoma (39.5%) and 8 patients (9.8%) developed VTE events. The calculated probability of VTE occurrence using KS, V-CATS and modified V-CATS scores at cut off levels ≥3 were 87.5%, 87.5%, 100% respectively. The AUC in ROC curve of modified Vienna CATS score showed significant difference when compared to that of V-CATS and KS (P= 0.047 and 0.029, respectively). Conclusion: Our data shows the usefulness of three VTE risk assessment models in hematological malignancies. Modified V-CATS score is more specific compared with V-CATS and KS, while all three scores have similar sensitivity. Implementation of RAM in hematological cancers can help improve the use of thromboprophylaxis.

Background: As pregnancy is a physiological prothrombotic state, pregnant women may be at increased risk of developing coagulopathic and/or thromboembolic complications associated with COVID-19. Objectives: To investigate the occurrence of haemostatic and thrombo-embolic complications in pregnant women with COVID-19. Search Strategy: Two biomedical databases were searched between September 2019 and June 2020 for case reports and series of pregnant women with COVID-19. Additional registry cases known to the authors were included. Steps were taken to minimise duplicate patients. Selection criteria: Pregnant women with COVID-19 based either on a positive swab or high clinical suspicion e.g. symptoms and radiographic evidence. Data Collection and Analysis: Information on coagulopathy based on abnormal coagulation test results or clinical evidence of disseminated intravascular coagulation (DIC), and on arterial or venous thrombosis, were extracted using a standard form. If available, detailed laboratory results and information on maternal outcomes were analysed. Main Results: 1063 women met the inclusion criteria, of which three (0.28%) had arterial and/or venous thrombosis, seven (0.66%) had DIC, and a further three (0.28%) had coagulopathy without meeting the definition of DIC. Five hundred and thirty-seven women (56%) had been reported as having given birth and 426 (40%) as having an ongoing pregnancy. There were 17 (1.6%) maternal deaths in which DIC was reported as a factor in two. Conclusions: Our data suggests that coagulopathy and thromboembolism are both increased in pregnancies affected by COVID-19. Detection of the former may be useful in the identification of women at risk of deterioration.